Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells

• Status: Recruiting
• Trial end date: 2020-12-31
• Target enrollment: 10
• Participant gender: All

Summary

Treatment of systemic lupus erythematosus with pooled allogenic mesenchymal stem cells

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
• Collaborator: Belarusian State Medical University

Criteria

Inclusion Criteria:

• SLE diagnosis (4 of 11 criteria by ACR);

• positive dsDNA;

• SELENA-SLEDAI index ≥6;

• active lupus nephritis;

• patient can read, understand and follow the procedures.

Exclusion Criteria:

• need for dialysis;

• planned renal transplantation;

• any medical condition which can be associated with the high risk for the patient;

• pregnancy/lactation;

• chronic infections, including hepatitis B/C, tuberculosis, HIV;

• any malignant tumor in the last 5 years.